Mefoglip2.5 mg+500 mg

Mefoglip is a fixed-dose combination oral antidiabetic indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Its use is classified by evidence strength as follows:

• Established/FDA-approved second-line use: in patients with type 2 diabetes mellitus whose hyperglycemia is not adequately controlled with diet and exercise plus either a sulfonylurea alone or metformin alone (i.e., stepping up from monotherapy that has become insufficient).
• Established/FDA-approved initial combination therapy: as initial pharmacologic therapy, together with diet and exercise, in patients whose hyperglycemia is unlikely to be controlled with monotherapy alone and who have not previously been treated with other antidiabetic agents, at the discretion of the prescriber.
• Not indicated for: type 1 diabetes mellitus or diabetic ketoacidosis, for which insulin is the required therapy.

Mefoglip is not a substitute for diet, exercise, and lifestyle modification, which remain the foundation of type 2 diabetes management.

Glipizide + Metformin Hydrochloride tablets contain two active pharmaceutical ingredients combined in a fixed-dose oral tablet:

• Glipizide - a second-generation sulfonylurea.
• Metformin hydrochloride - a biguanide.

Glipizide + Metformin Hydrochloride is available in different strength combinations (e.g., glipizide 2.5 mg/metformin hydrochloride 250 mg, glipizide 2.5 mg/metformin hydrochloride 500 mg, and glipizide 5 mg/metformin hydrochloride 500 mg), along with standard pharmaceutical excipients. The exact strength and excipient profile can vary by manufacturer; refer to the product-specific pack insert for the precise composition of the formulation dispensed.

Mefoglip is an oral fixed-dose combination antidiabetic medicine that brings together two complementary mechanisms of blood glucose control in a single tablet. It combines glipizide, a sulfonylurea that stimulates the pancreas to release more insulin, with metformin hydrochloride, a biguanide that reduces the liver's glucose output and improves the body's response to insulin.

Mefoglip is used in adults with type 2 diabetes mellitus who need more than one oral agent, or an alternative to starting with a single agent, to achieve adequate blood sugar control alongside diet and exercise. It is taken by mouth, typically with meals, and is not used for type 1 diabetes or diabetic ketoacidosis.

Mefoglip belongs to the class of oral antidiabetic fixed-dose combinations, combining a sulfonylurea (glipizide) with a biguanide (metformin hydrochloride). It is used for the management of type 2 diabetes mellitus.

Glipizide + Metformin Hydrochloride combines two agents with complementary and largely independent mechanisms of action for lowering blood glucose in type 2 diabetes:

• Glipizide (sulfonylurea): lowers blood glucose primarily by stimulating the release of insulin from functioning pancreatic beta cells. It binds to sulfonylurea receptors on beta-cell membranes, closing ATP-sensitive potassium channels, which depolarizes the cell and triggers calcium influx and insulin secretion. It requires a functioning pancreas to be effective.
• Metformin hydrochloride (biguanide): lowers blood glucose by decreasing hepatic glucose production (reduced gluconeogenesis and glycogenolysis), decreasing intestinal absorption of glucose, and increasing peripheral glucose uptake and utilization by improving insulin sensitivity. Unlike glipizide, it does not stimulate insulin secretion and therefore does not cause hypoglycemia when used alone.

Used together in Glipizide + Metformin Hydrochloride, these two mechanisms act on both insulin secretion and insulin action, providing complementary glycemic control.

Pharmacokinetics (brief): Glipizide is well absorbed orally, highly protein bound, hepatically metabolized, with a plasma half-life of about 2-5 hours. Metformin is absorbed from the small intestine, is not protein bound or hepatically metabolized, and is eliminated essentially unchanged by the kidneys; renal function therefore directly affects metformin clearance and accumulation risk.

Mefoglip should be taken orally with food (meals), which helps reduce gastrointestinal side effects and the risk of hypoglycemia. Tablets should be swallowed whole and not crushed or chewed unless specifically directed. Doses are typically given once or twice daily depending on the prescribed regimen. Take Mefoglip at consistent times relative to meals each day, and do not skip meals after a dose.

Mefoglip has clinically significant interactions related to both of its components:

• Alcohol: Concurrent alcohol intake increases the risk of metformin-associated lactic acidosis and can potentiate the hypoglycemic effect of glipizide. Excessive alcohol use should be avoided.
• Iodinated contrast media: Use of intravascular iodinated contrast agents can acutely impair renal function and precipitate lactic acidosis in patients taking metformin; Mefoglip should be temporarily discontinued at or before the imaging procedure and withheld for 48 hours afterward, restarting only after renal function is confirmed normal.
• Drugs affecting renal clearance (e.g., cationic drugs eliminated by renal tubular secretion such as cimetidine): may compete with metformin for renal tubular transport, increasing metformin levels and lactic acidosis risk.
• Other antidiabetic agents and insulin: concomitant use increases the risk of hypoglycemia; dose adjustment and monitoring are needed.
• Beta-blockers: may mask the warning signs and symptoms of hypoglycemia caused by the glipizide component.
• Drugs that raise blood glucose (e.g., corticosteroids, thiazide diuretics, certain sympathomimetics): may reduce glycemic control and require dose reassessment.
• CYP2C9 inhibitors/inducers (e.g., fluconazole, rifampin): may alter glipizide metabolism, increasing hypoglycemia risk or reducing efficacy respectively.

Inform the prescriber of all other medicines, supplements, and alcohol use before starting Mefoglip.

Side effects of Mefoglip arise from both its glipizide and metformin components. Common side effects include:

• Gastrointestinal effects: nausea, vomiting, diarrhea, abdominal discomfort, flatulence, and a metallic taste (mainly from the metformin component, often reduced by taking with food and gradual dose titration).
• Hypoglycemia (low blood sugar): the most common adverse effect attributable to the glipizide component, more likely with irregular meals, increased physical activity, alcohol use, or in elderly/renally-impaired patients.
• Headache, dizziness, and asthenia (weakness).

Less common but serious effects include lactic acidosis (see Contraindications and Precautions) and, with long-term use, vitamin B12 deficiency. Seek prompt medical attention for symptoms of severe hypoglycemia (confusion, sweating, palpitations, loss of consciousness) or lactic acidosis (unusual muscle pain, difficulty breathing, unusual tiredness, abdominal pain, feeling cold, dizziness, slow or irregular heartbeat).

Mefoglip is generally not recommended during pregnancy. Persistent hyperglycemia in pregnancy is associated with a higher risk of congenital malformations; insulin is generally preferred for glycemic control during pregnancy because it does not cross the placenta to a clinically significant degree. Mefoglip should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus, and only under the direction of a physician.

Metformin is known to pass into breast milk in small amounts, and glipizide's transfer into breast milk has not been well characterized; because of the potential for hypoglycemia in a nursing infant, a decision should be made whether to discontinue nursing or discontinue Mefoglip, taking into account the importance of the drug to the mother, in consultation with a physician.

The following precautions apply to Mefoglip:

• Lactic acidosis: a rare but serious risk from the metformin component; see boxed warning under Contraindications. Use caution and monitor renal function, especially in the elderly, and in those with dehydration, sepsis, or acute illness.
• Hypoglycemia: the glipizide component can cause hypoglycemia, particularly with irregular or skipped meals, increased exercise, alcohol intake, and in elderly patients or those with renal or hepatic impairment. Patients should be counseled to recognize and manage hypoglycemia symptoms.
• Alcohol use: should be limited or avoided, as it increases the risk of both lactic acidosis and hypoglycemia (see Interactions).
• Vitamin B12 deficiency: long-term metformin use may reduce vitamin B12 absorption; periodic monitoring of hematologic parameters and vitamin B12 levels is reasonable, especially in patients with anemia or peripheral neuropathy.
• Renal and hepatic function: should be assessed before starting and periodically during treatment, given the impact of both organs on drug clearance and lactic acidosis risk.
• Surgical procedures: Mefoglip should generally be temporarily discontinued at the time of, or prior to, surgery with restricted food and fluid intake, and restarted only after oral intake resumes and renal function is confirmed stable.

Patients should carry identification noting their diabetes and current medicines, including Mefoglip, especially given the hypoglycemia risk.

Overdose of Mefoglip can cause severe hypoglycemia (from the glipizide component), which may present with confusion, sweating, tremor, seizures, or loss of consciousness, and/or lactic acidosis (from the metformin component), which is a medical emergency. If an overdose of Mefoglip is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Do not attempt to manage a suspected overdose at home; hospital-based monitoring and supportive care (which may include glucose administration for hypoglycemia or hemodialysis for significant lactic acidosis) may be required.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Older adults are at increased risk of both hypoglycemia (glipizide component) and lactic acidosis (metformin component), often related to age-related decline in renal function. Mefoglip should be used cautiously in the elderly, starting at a low dose with close monitoring of renal function and blood glucose.

Renal impairment: Mefoglip is contraindicated in severe renal impairment (see Contraindications); use with caution and reduced dosing in mild-to-moderate impairment, with regular monitoring.

Hepatic impairment: Generally avoided, as hepatic disease increases lactic acidosis risk and can affect glipizide clearance.

Pediatric patients: Safety and efficacy of Mefoglip have not been established in patients under 18 years of age; not recommended for pediatric use.

Pregnancy and lactation: See Pregnancy and Lactation section.

Mefoglip is generally used long-term as part of ongoing management of type 2 diabetes mellitus, alongside diet and exercise. There is no fixed treatment duration; the physician periodically reassesses blood glucose control (e.g., via HbA1c), renal and hepatic function, and tolerability to determine whether Mefoglip should be continued, adjusted, or supplemented/replaced with other therapy. Do not stop Mefoglip without medical advice, as this can lead to loss of glycemic control.

Oral antidiabetic fixed-dose combination (sulfonylurea + biguanide)

Glipizide + Metformin Hydrochloride works through two complementary mechanisms: the glipizide component stimulates pancreatic beta cells to secrete more insulin by closing ATP-sensitive potassium channels on the beta-cell membrane, while the metformin hydrochloride component reduces hepatic glucose production, decreases intestinal glucose absorption, and improves peripheral tissue sensitivity to insulin. Together, these actions lower blood glucose through both increased insulin availability and improved insulin action.

C

The safety and efficacy of Mefoglip have not been established in pediatric patients (under 18 years of age). Mefoglip is therefore not recommended for use in children or adolescents; alternative antidiabetic therapy appropriate for pediatric type 2 diabetes should be used under specialist guidance.